Abbisko Reports Promising Liver Cancer Treatment Results

Abbisko Cayman Limited (HK:2256) has released an update.

Abbisko Therapeutics has revealed encouraging phase II trial results for their novel treatment combination of irpagratinib and atezolizumab in advanced hepatocellular carcinoma, demonstrating a 50% objective response rate in particular patient groups. The company aims to further investigate this treatment strategy, potentially offering a new hope for patients with this common and deadly form of liver cancer. While promising, the company cautions investors about the certainty of the drug reaching market success.

For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.